July 2015, Volume :115 Number 7 , page 24 - 25 [Buy]
Join NursingCenter to get uninterrupted access to this Article
* Filgrastim-sndz (Zarxio) is the first biosimilar product approved in the United States. It has been determined to be biosimilar to filgrastim (Neupogen).
Join NursingCenter on Social Media to find out the latest news and special offers
© 2025 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer – Your California Privacy Choices -- v10.05.00